Skip to main content

Table 4 Estimated effect (EE) and effect size (ES) of early engagement in Didactic Webinars

From: Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes

 

Early engagement with a prescriber vs. Did not engage

Early engagement without a prescriber vs. Did not engage

Early engagement with a prescriber vs. Early engagement without a prescriber

Q1

Q2

Q3

Q1

Q2

Q3

Q1

Q2

Q3

Reach

 Number of patients on OUD

  EE (95% CI)

−12.98 (−1565.22, 1539.26)

−7.63 (−702.28, 687.03)

−2.27 (−1554.45, 1549.91)

−4.21 (−1829.63, 1821.21)

10.04 (−943.41, 963.50)

24.30 (−1801.41, 1850.00)

−8.77 (−1190.90, 1173.36)

−17.67 (−635.76, 600.43)

−26.57 (−1209.28, 1156.15)

  ES (95% CI)

−0.16 (−19.65, 19.33)

−0.10 (−8.82, 8.63)

−0.03 (−19.52, 19.46)

−0.05 (−22.97, 22.87)

0.13 (−11.84, 12.10)

0.31 (−22.62, 23.23)

−0.11 (−14.95, 14.73)

−0.22 (−7.98, 7.54)

−0.33 (−15.18, 14.52)

 Number of patients prescribed MOUD

  EE (95% CI)

−1.29 (−44.71, 42.13)

2.05 (−24.66, 28.77)

5.40 (−38.03, 48.82)

6.91 (−46.69, 60.51)

8.81 (−27.74, 45.37)

10.72 (−42.88, 64.32)

−8.20 (−43.00, 26.61)

−6.76 (−30.53, 17.02)

−5.32 (−40.13, 29.48)

  ES (95% CI)

−0.08 (−2.83, 2.67)

0.13 (−1.56, 1.82)

0.34 (−2.41, 3.09)

0.44 (−2.96, 3.83)

0.56 (−1.76, 2.87)

0.68 (−2.71, 4.07)

−0.52 (−2.72, 1.68)

−0.43 (−1.93, 1.08)

−0.34 (−2.54, 1.87)

 Percent of patients prescribed MOUDa

  EE (95% CI)

10.24 (0.28, 20.20)

−8.34 (−16.26, −0.43)

−26.93 (−35.23, −18.63)

8.15 (3.26, 13.03)

−11.30 (−15.46, −7.15)

−30.75 (−35.54, −25.96)

2.10 (−4.88, 9.07)

2.96 (−2.04, 7.95)

3.82 (−2.63, 10.28)

  ES (95% CI)

0.28 (0.01, 0.56)

−0.23 (−0.45, −0.01)

−0.75 (−0.98, −0.52)

0.23 (0.09, 0.36)

−0.31 (−0.43, −0.20)

−0.85 (−0.99, −0.72)

0.06 (−0.14, 0.25)

0.08 (−0.06, 0.22)

0.11 (−0.07, 0.29)

Adoption

 Number of prescribers

  EE (95% CI)

1.40 (−2.89, 5.69)

0.40 (−3.37, 4.17)

−0.60 (−4.89, 3.69)

2.06 (−3.34, 7.47)

1.53 (−3.34, 6.40)

1.00 (−4.41, 6.40)

−0.66 (−4.30, 2.97)

−1.13 (−4.42, 2.16)

−1.60 (−5.24, 2.04)

  ES (95% CI)

0.75 (−1.56, 3.06)

0.21 (−1.81, 2.24)

−0.32 (−2.63, 1.98)

1.11 (−1.80, 4.01)

0.82 (−1.80, 3.44)

0.54 (−2.37, 3.44)

−0.36 (−2.31, 1.60)

−0.61 (−2.38, 1.16)

−0.86 (−2.82, 1.10)

 Number of x-waivered prescribers

  EE (95% CI)

1.45 (0.02, 2.88)

1.80 (0.59, 3.01)

2.15 (0.72, 3.58)

1.24 (−0.62, 3.11)

0.87 (−0.77, 2.51)

0.49 (−1.37, 2.36)

0.21 (−0.91, 1.33)

0.93 (−0.04, 1.91)

1.66 (0.54, 2.78)

  ES (95% CI)

0.55 (0.01, 1.09)

0.68 (0.22, 1.14)

0.81 (0.27, 1.36)

0.47 (−0.24, 1.18)

0.33 (−0.29, 0.95)

0.19 (−0.52, 0.89)

0.08 (−0.35, 0.50)

0.35 (−0.02, 0.72)

0.63 (0.20, 1.05)

 Number of active x-waivered prescribers

  EE (95% CI)

0.36 (−0.26, 0.99)

0.46 (−0.05, 0.96)

0.56 (−0.07, 1.18)

0.26 (−0.55, 1.08)

0.01 (−0.68, 0.70)

−0.24 (−1.05, 0.58)

0.10 (−0.43, 0.63)

0.45 (0.00, 0.90)

0.79 (0.26, 1.32)

  ES (95% CI)

0.20 (−0.14, 0.53)

0.25 (−0.02, 0.52)

0.30 (−0.04, 0.64)

0.14 (−0.30, 0.58)

0.01 (−0.36, 0.38)

−0.13 (−0.57, 0.31)

0.05 (−0.23, 0.34)

0.24 (0.00, 0.48)

0.43 (0.14, 0.71)

 Percent of x-waivered prescribers

  EE (95% CI)

0.81 (−0.36, 1.97)

5.62 (4.56, 6.68)

10.44 (9.27, 11.60)

−1.44 (−2.78, −0.09)

−0.55 (−1.79, 0.68)

0.33 (−1.02, 1.67)

2.24 (1.39, 3.09)

6.18 (5.39, 6.96)

10.11 (9.26, 10.96)

  ES (95% CI)

0.04 (−0.02, 0.09)

0.26 (0.21, 0.30)

0.47 (0.42, 0.53)

−0.07 (−0.13, −0.00)

−0.03 (−0.08, 0.03)

0.02 (−0.05, 0.08)

0.10 (0.06, 0.14)

0.28 (0.25, 0.32)

0.46 (0.42, 0.50)

Implementation

 IMAT implementation quality

  EE (95% CI)

–

–

0.05 (−0.04, 0.14)

–

–

−0.09 (−0.21, 0.03)

–

–

0.14 (0.06, 0.22)

  ES (95% CI)

–

–

0.08 (−0.06, 0.23)

–

–

−0.15 (−0.35, 0.05)

–

–

0.23 (0.10, 0.36)

  1. aPrimary outcome; EE and ES in bold indicated 95% CI did not cross zero